The 2005 Chawla-Rosenfeld Symposium on Developmental Therapeutics for Sarcoma Introduction George D. Demetri, MD Dana-Farber Cancer Institute Harvard Medical.

Slides:

Advertisements

Similar presentations

Inhibition of the mTOR and MAPK pathways in the treatment of osteosarcoma Kathleen M. Diehl, M.D. FACS Assistant Professor University of Michigan.

Advertisements

v SCF Ras GDP Inactive nucleus SCF Ras GDP Inactive nucleus.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Cancer (MBoC): Fundamental and Evolving Concepts slide presentation.

George D. Demetri Graduated: Stanford Medical School Residency: Univ. of Washington Hospitals Internal Medicine Fellowship: Dana Farber Cancer Institute,

Rapid Learning Precision Oncology. Part I: Patient’s Perspective Part II: Industry Perspective Part III: Aligning Incentives.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcoma Coordinating Investigator:

A Mediating Effect of AKT in EGFR Signal to Osteosarcomas in a Clinical Study Huiyun Wu, Adriana Gonzalez, and Yu Shyr Vanderbilt-Ingram Cancer Center,

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Breast Cancer slide presentation is not an independent educational.

September, 2006 GIST Clinical Trials Life Fest 2006 Jerry Call.

Clinical Trials Explained and Explored

In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.

Signal Transduction II Transduction Proteins & Second Messengers.

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Current Situation of Breast Cancer Treatment in US Stefan Glück MD PhD Professor of Medicine Clinical Director Braman Family Breast Cancer Institute UMSylvester.

Overcoming Treatment Challenges in Sarcomas: Promising Novel Targeted Agents George D. Demetri, MD Center for Sarcoma and Bone Oncology Dana-Farber Cancer.

High Expression of Ezrin, a Determinant of Metastatic Behavior, in Ewing’s Sarcoma Kartik Krishnan, Gaurav Khanna, Stephen Hewitt, Chand Khanna, and Lee.

Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.

SARC Developmental Therapeutics Committee Update Chand Khanna Open Science: Biology to Therapy” SARC Developmental Therapeutics Committee Update Chand.

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

SARC studies: an overview

SARC Initially the North American Consortium of CTOS 501.c.3 organization Incorporated November 2003.

Underlying Principles and Future Targets for Molecular Therapy of SCCHN Prof. Tim H. Brümmendorf Dept. of Hematology and Oncology University Hospital Eppendorf.

CTOS IS TEN YEARS OLD SARC IS TWO YEARS OLD Happy Birthday, CTOS, SARC.

Insights into normal cell biology Targets for diagnosis and follow-up

 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.

1 Advocacy Session Sarcoma Research Funding by the Nonprofit Sector Jody Cummings, MPH Executive Director Jody Cummings, MPH Executive Director.

1 Hepatocellular Carcinoma Overview of Hepatocellular Carcinoma Epidemiology.

How to present a scientific paper Dr. Rebecca B. Riggins Department of Oncology, Georgetown University

INTERGROUP COALITION AGAINST SARCOMAS (ICAS) SCIENTIFIC STEERING COMMITTEE: EC Borden, G Demetri, M von Mehren, K Albritton, P Pisters BIOSTATISTICS: C.

Phase II Study of Dasatinib (BMS ) in Advanced Sarcomas and Chordoma Coordinating Center: U Michigan.

The Basis of Genetics. The Cell Cycle Cell Signaling.

Extracellular Environment. Extracellular Environment.

SARC Restructuring. SARC Strategic Plan  Mission  Given there is no successful structure in the US to provide platform to make progress in the diagnosis.

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

Jon Trent, MD, PhD Professor of Medicine Sarcoma Medical Oncology The University of Miami, Sylvester Cancer Center Gastrointestinal Stromal Tumor Advanced.

INTRODUCTION Gastrointestinal stromal tumor (GIST) is a rare disorder and only a small fraction of affected patients are children. The rarity of this tumor,

1 Trends in drug development programs in the era of Personalized Medicine Gunnar Saeter, M.D., Ph.D. Head, Institute for Cancer Research Oslo University.

PHL 616 Drug Discovery & Development Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:

Pediatric GIST: KIT inhibitors & IGF1R-directed antibodies January 22, 2009 Katherine Janeway, MD.

TARGETING HSP90 IN IM-RESISTANT GIST:

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Preclinical Pathway to Host-Directed Therapy for TB/HIV Co-Infection

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Advances in Molecular Biology of Lung Disease

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

Sustaining Proliferative Signaling and Evading Growth Suppressors

Underlying Mechanisms for Distant Metastasis - Molecular Biology

Figure 4 Possible combination therapies CDK4/6 inhibitors

Personalizing Therapy for Colorectal Cancer

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

Phase I Drug Development: Early Indications of Antitumor Activity for Sarcoma Patients and Opportunities for Progress Anthony Tolcher Director of Clinical.

Nat. Rev. Urol. doi: /nrurol

Personalizing Therapy for Colorectal Cancer

Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic.

Targeted Therapies in Melanoma: Translational Research at Its Finest

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

Toru Furukawa Clinical Gastroenterology and Hepatology

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

Nat. Rev. Urol. doi: /nrurol

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Vascular Endothelial Growth Factor (VEGF) Pathway

Cancer is a Challenge Cancer is common in humans – a public health problem ~1 of every 3 women will develop cancer ~1 of every 2 men will develop cancer.

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

Scientific Symposium Opening session CTOS (1 pm to 5 pm)

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Platelet-derived growth factor (PDGF) signalling pathway.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Brief Review – Growth Factors and Receptors

Presentation transcript:

The 2005 Chawla-Rosenfeld Symposium on Developmental Therapeutics for Sarcoma Introduction George D. Demetri, MD Dana-Farber Cancer Institute Harvard Medical School Ludwig Institute for Cancer Research

Developmental Therapeutics in Sarcomas Sarcomas are now recognized as important models for rational drug discovery and accelerated clinical developmentSarcomas are now recognized as important models for rational drug discovery and accelerated clinical development Our field needs to expand this beyond targeted therapies for GISTOur field needs to expand this beyond targeted therapies for GIST

Developmental Therapeutics in Sarcomas Today’s Topic: Expanding the preclinical and clinical collaborations to accelerate discovery and application in sarcoma researchToday’s Topic: Expanding the preclinical and clinical collaborations to accelerate discovery and application in sarcoma research –Peter Houghton, PhD: cancer modeling –Rich Gorlick, MD: osteosarcoma frontiers –Antony Tolcher, MD: phase I to sarcomas –Chand Khanna, PhD, DVM: sarcoma research is going to the dogs

The Question What is the next great target for a specific subtype of sarcoma?

Which are the BEST Molecular Targets in Sarcomas? Receptor Tyrosine Kinase RAS-GDP RAF-1 SHC BAD SOS GRB Nucleus BCLX LMitochondria SRC P STAT1+3 P RAS-GTP SAPK P AKT BAD P RAS-GAP DOK ? MYC PI3K MEK1/2 P P P P P MAPK mTOR P P

Which are the BEST Molecular Targets in Sarcomas? Receptor Tyrosine Kinase RAS-GDP RAF-1 SHC BAD SOS GRB Nucleus BCLX LMitochondria SRC P STAT1+3 P RAS-GTP SAPK P AKT BAD P RAS-GAP DOK ? MYC PI3K MEK1/2 P P P P P MAPK mTOR P Sutent (Pfizer) P Gleevec (Novartis)

Molecular Targets in SARCOMAS Receptor Tyrosine Kinase RAS-GDP RAF-1 SHC BAD SOS GRB Nucleus BCLX LMitochondria SRC P STAT1+3 P RAS-GTP SAPK P AKT BAD P RAS-GAP DOK ? MYC PI3K MEK1/2 P P P P P MAPK mTOR P Sutent (Pfizer) P Zarnestra (JNJ) P PI3kI (PIRAMED) P RAD001 (Novartis) CCI779 (Wyeth) AP23573 (ARIAD) P SORAFENIB (Bayer) Imatinib (Novartis) P BMS (Bristol-MS)

Molecular Targets in SARCOMAS Receptor Tyrosine Kinase RAS-GDP RAF-1 SHC BAD SOS GRB Nucleus BCLX LMitochondria SRC P STAT1+3 P RAS-GTP SAPK P AKT BAD P RAS-GAP DOK ? MYC PI3K MEK1/2 P P P P P MAPK mTOR P Sutent (Pfizer) P Zarnestra (JNJ) P PI3kI (PIRAMED) P RAD001 (Novartis) CCI779 (Wyeth) AP23573 (ARIAD) P SORAFENIB (Bayer) Imatinib (Novartis) P BMS (Bristol-MS) DRUG X DRUG Y DRUG Z DRUG BDRUG C DRUG D

Molecular Targets in SARCOMAS Receptor Tyrosine Kinase RAS-GDP RAF-1 SHC BAD SOS GRB Nucleus BCLX LMitochondria SRC P STAT1+3 P RAS-GTP SAPK P AKT BAD P RAS-GAP DOK ? MYC PI3K MEK1/2 P P P P P MAPK mTOR P Sutent (Pfizer) P Zarnestra (JNJ) P PI3kI (PIRAMED) P RAD001 (Novartis) CCI779 (Wyeth) AP23573 (ARIAD) P SORAFENIB (Bayer) Imatinib (Novartis) P BMS (Bristol-MS) DRUG X DRUG Y DRUG Z DRUG BDRUG C DRUG D DRUG X DRUG Z N DRUG Z X DRUG Z y DRUG Z N DRUG Z A DRUG Z N DRUG Z Z DRUG Z N

SARC CTOS Building Effective Collaborations with SARC and others to Answer These Important Questions International Sarcoma Research Groups US Govt ResearchMechanisms Sarcoma Intergroups Individual Investigators Patient Advocacy Groups